GlassScriptPhysician profile
Mary B Butcher
NPI 1366540379
$2,836.44
in general payments reported to CMS, 2019-2025
21 companies · $583 in 2025
The $583 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $240 · 2020: $175 · 2021: $308 · 2022: $455 · 2023: $431 · 2024: $644 · 2025: $583.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,659.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,658.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Azurity Pharmaceuticals, INC. | $753.42 | 2023-2025 | Edarbyclor, Edarbyclor, Edarbi |
| Abbvie INC. | $339.10 | 2019-2023 | Ubrelvy |
| Arbor Pharmaceuticals, INC. | $240.47 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $225.99 | 2019-2025 | Airsupra, Farxiga |
| Kowa Pharmaceuticals America, INC. | $196.49 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $180.92 | 2021-2024 | Dificid |
| Ibsa Pharma INC. | $175.26 | 2020-2025 | Tirosint, Tirosint, Licart |
| Lilly USA, LLC | $103.42 | 2024-2025 | Zepbound, Mounjaro |
| Novo Nordisk INC | $96.42 | 2019-2025 | Wegovy |
| Paratek Pharmaceuticals, INC. | $92.83 | 2023-2024 | Nuzyra |
| Exact Sciences Corporation | $83.51 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $68.61 | 2023-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.72 | 2020-2024 | Trulance, Xifaxan |
| Pfizer INC. | $46.45 | 2019-2024 | |
| Axsome Therapeutics, INC. | $41.41 | 2025 | Auvelity |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $29.41 | 2024 | Unithroid |
| Antares Pharma, INC. | $28.37 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $24.83 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $22.94 | 2021 | |
| Astellas Pharma US INC | $17.86 | 2025 | Veozah |
| Currax Pharmaceuticals LLC | $16.01 | 2019-2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Butcher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.